Cys-MC-GGFG-Dxd

Cys-MC-GGFG-Dxd is a conjugate of Cys and Deruxtecan (HY-13631E) . Cys-MC-GGFG-Dxd is a linker-toxin building block in antibody-drug conjugates (ADCs) used to link antibody Cys residues to cytotoxic drugs. Cys-MC-GGFG-Dxd can be used in cancer research[1][2].

Product Specifications

CAS Number

[3025787-83-8]

UNSPSC

12352203

Target

Drug-Linker Conjugates for ADC

Related Pathways

Antibody-drug Conjugate/ADC Related

Applications

Cancer-programmed cell death

Field of Research

Cancer

Purity

99.01

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

O=C(CC(SC[C@H](N)C(O)=O)C1=O)N1CCCCCC(NCC(NCC(N[C@@H](CC2=CC=CC=C2)C(NCC(NCOCC(N[C@@H]3C4=C(CN5C6=CC7=C(COC([C@]7(O)CC)=O)C5=O)C6=NC8=CC(F)=C(C)C(CC3)=C48)=O)=O)=O)=O)=O)=O

Molecular Formula

C55H63FN10O15S

Molecular Weight

1155.21

References & Citations

[1]Peng H. Perspectives on the development of antibody-drug conjugates targeting ROR1 for hematological and solid cancers. Antib Ther. 2021 Oct 15;4 (4) :222-227.|[2]Ogitani Y, et al. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Sci. 2016 Jul;107 (7) :1039-46.